tldrdailynews.com logo

Viking Therapeutics' Weight-Loss Drug Trial Results Propel Stock to Soar

1 min read
Source: CNBC
Viking Therapeutics' Weight-Loss Drug Trial Results Propel Stock to Soar
Photo: CNBC
TL;DR

Viking Therapeutics' stock surged 80% after positive results from a mid-stage trial of its experimental weight loss drug, VK2735, which showed significant weight loss in patients with obesity or overweight. The drug, targeting GLP-1 and GIP hormones, demonstrated promising initial results with encouraging safety and tolerability. Analysts suggest potential acquisition interest from larger pharmaceutical companies, as the weight loss drug market is projected to grow into a $100 billion industry.

Topics:businessbusinesshealthcare#businesshealthcare#clinical-trial#obesity#pharmaceutical-industry#viking-therapeutics#weight-loss-drug
Share this article
  1. Viking Therapeutics stock jumps 80% after positive weight loss drug trial results  CNBC
  2. Viking Catapults 79% As Weight-Loss Drugs Beats Out Lilly's Zepbound  Investor's Business Daily
  3. Obesity drug from Viking hits in trial, fueling competition in the field  STAT
  4. Viking Therapeutics’ stock doubles as investors cheer cheap entry to weight-loss drug craze  MarketWatch
  5. Viking Therapeutics Stock Surges 100% on Positive Weight-Loss Drug Trial  Barron's

Want the full story? Read the original reporting

Read on CNBC